BCR and ovarian cancer: Future studies should further integrate single-cell histology, spatial transcriptome and TCR/BCR profile tracking to clarify the functional status and dynamic evolutionary pathways of different subtypes of immune cells; meanwhile, strengthen the design of multi-targeted combinatorial therapies to break through the current bottleneck of the efficacy of ICIs in ovarian cancer.